Ritract Limited is pleased to announce that it has been granted a US Patent and a South African Patent for its retractable safety syringe technology. These patents have been granted for an “Improved non-reusable syringe” for which the Australian Patent was granted on 22 April 2005 as previously announced.
The granting of a US Patent in particular is of paramount importance in the realisation of the full value of Ritract’s Intellectual Property in the largest potential market for the product.
The Ritract syringe patent is pending in a further 31 countries including key countries in Europe and Asia. Over the coming months the Patent Offices in these markets are expected to follow the lead set by Australia, the United States and South Africa.
These patents are important additions to the existing portfolio of patents held by the Company advancing the Company’s intellectual property strategy to acquire safety technology in the medical devices sector. Ritract’s intellectual property portfolio comprise 4 patents, all of which have been granted in Australia and US. In addition, our IP portfolio includes the trademark Ritract®, a registered trademark.
Ritract Limited Managing Director, Rupert Northcott said “The grant of a US patent for our technology further confirms the strength of our intellectual property, and is especially satisfying given the amount of patent activity in the safety syringe sector.”